Contact
searchSearch
HMP Global
Login

Multiple Myeloma Excellence Forum

Multiple Myeloma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Hang Quach, MD, FRACP, FRCPA, MBBS
Videos
Trispecific Antibody Therapy Well-Tolerated Among Patients With Relapsed/Refractory Multiple Myeloma
01/06/2025
According to a phase 1 dose escalation study among patients with relapsed/refractory multiple myeloma, treatment with novel BCMA-CD38-CD3-targeting trispecific antibody ISB 2001 was well-tolerated.
According to a phase 1 dose escalation study among patients with relapsed/refractory multiple myeloma, treatment with novel BCMA-CD38-CD3-targeting trispecific antibody ISB 2001 was well-tolerated.
According to a phase 1 dose...
01/06/2025
Oncology
Meletios-Athanasios Dimopoulos, MD
Videos
Daratumumab Monotherapy Shows Benefit vs Active Monitoring for Patients With High-Risk Smoldering Multiple Myeloma
12/08/2024
Meletios-Athanasios Dimopoulos, MD, discusses findings from the phase 3 Aquila study which demonstrated the benefit of daratumumab monotherapy compared to active monitoring for patients with high-risk smoldering multiple myeloma.
Meletios-Athanasios Dimopoulos, MD, discusses findings from the phase 3 Aquila study which demonstrated the benefit of daratumumab monotherapy compared to active monitoring for patients with high-risk smoldering multiple myeloma.
Meletios-Athanasios Dimopoulos,...
12/08/2024
Oncology
Saad Usmani, MD
Conference Coverage
Exploring the Current Treatment Landscape for Patients With Extramedullary MM
10/29/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Saad Usmani, MD, discusses optimal strategies and the current treatment landscape for patients with extramedullary multiple myeloma.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Saad Usmani, MD, discusses optimal strategies and the current treatment landscape for patients with extramedullary multiple myeloma.
At the 2024 Lymphoma, Leukemia &...
10/29/2024
Lymphoma, Leukemia & Myeloma Network
Mark Bustoros, MD
Conference Coverage
Identifying Unmet Clinical Needs in Treating Patients With Extramedullary MM
10/28/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mark Bustoros, MD, shares expert insight into the unmet clinical needs in targeting and treating patients with extramedullary multiple myeloma, an aggressive subtype of myeloma.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mark Bustoros, MD, shares expert insight into the unmet clinical needs in targeting and treating patients with extramedullary multiple myeloma, an aggressive subtype of myeloma.
At the 2024 Lymphoma, Leukemia &...
10/28/2024
Lymphoma, Leukemia & Myeloma Network
Bruno Paiva, PhD
Conference Coverage
Exploring the Immune Microenvironment in Multiple Myeloma Treatment
10/25/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Bruno Paiva, PhD, shared expert insight into the immune determinants of response and resistance among patients with multiple myeloma, highlighting the need to bring immune biomarkers into the...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Bruno Paiva, PhD, shared expert insight into the immune determinants of response and resistance among patients with multiple myeloma, highlighting the need to bring immune biomarkers into the...
At the 2024 Lymphoma, Leukemia &...
10/25/2024
Lymphoma, Leukemia & Myeloma Network
Joseph Mikhael, MD
Conference Coverage
Treatment Options for When Immune Therapies Fail Among Patients With R/R MM
10/24/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment possibilities for patients with 
R/R multiple myeloma when immune therapies, such as antibody drug conjugates, CAR T-cell therapy, and bispecific...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment possibilities for patients with 
R/R multiple myeloma when immune therapies, such as antibody drug conjugates, CAR T-cell therapy, and bispecific...
At the 2024 Lymphoma, Leukemia &...
10/24/2024
Lymphoma, Leukemia & Myeloma Network
Joshua Richter, MD
Conference Coverage
Evaluating the Use of MRD in Multiple Myeloma Treatment
10/19/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joshua Richter, MD, discusses the role of measurable residual disease in the treatment of patients with multiple myeloma.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joshua Richter, MD, discusses the role of measurable residual disease in the treatment of patients with multiple myeloma.
At the 2024 Lymphoma, Leukemia &...
10/19/2024
Lymphoma, Leukemia & Myeloma Network
Jonathan Kaufman, MD
Videos
Updates in Novel and Cellular Therapies for Patients With R/R Multiple Myeloma  
09/12/2024
Jonathan Kaufman, MD, discusses recent updates for treating patients with relapsed/refractory multiple myeloma with new and immune cellular therapies.
Jonathan Kaufman, MD, discusses recent updates for treating patients with relapsed/refractory multiple myeloma with new and immune cellular therapies.
Jonathan Kaufman, MD, discusses...
09/12/2024
Oncology
Oncology Advances: Long-Term Efficacy and Safety Results on Talquetamab Treatment for Patients With R/R Multiple Myeloma
Ajai Chari, MD
Videos
Should Additional BCMA Therapy be Utilized After Prior BCMA Treatment for Multiple Myeloma?
07/31/2024
Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued in favor of using additional BCMA-directed therapy after prior BCMA-directed therapy for patients with multiple myeloma.
Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued in favor of using additional BCMA-directed therapy after prior BCMA-directed therapy for patients with multiple myeloma.
Ajai Chari, MD, participated in...
07/31/2024
Oncology

Section Editor

Shaji Kumar, MD
Mayo Clinic, Rochester, Minnesota

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use